Antibody Humanization Service
Immunogenicity can potentially lead to reduced efficacy through rapid clearance or neutralization of the drug, or toxicity due to cross-reaction with proteins in the body, which can have catastrophic consequences for the patient. Antibody humanization is used for reducing the immunogenicity of animal monoclonal antibodies and for improving their activities in the human immune system. It is a very important step in therapeutic antibody discovery process.
KMD Bioscience have developed three antibody humanization strategies based on our phage display technology and we can preserve the specificity and affinity of the antibody toward the antigen whereas significantly or completely eliminate the immunogenicity of the antibody in humans.
CDR-Grafting Antibodies: This process involves transferring the antibody CDRs into a proper human antibody framework, while retaining its original affinity and specificity. Such as grafting of the murine CDRs into human frameworks.
Chimeric Antibodies: Creation of chimeric antibodies (non-human variable regions with human constant regions) can partially alleviate immunogenic response. Transfected to mammalian cells for recombinant antibody expression using DNA recombination technology.
Fully Humanized Antibodies: Using gene editing technology, the antibody gene in animal somatic cells were replaced by human, and the humanized antibodies was produced directly after animal immunization.
Service Highlights:
*Extensive experiences: We have many years’ experience and a strong track record in antibody engineering for therapeutic and diagnostic development.
*Multiple strategies: human framework selection, CDR (Complementarity-determining regions) back mutation library screening, etc.
*Guaranteed Affinity: The humanized antibody is guaranteed to have comparable binding affinity with parental antibody.
*High success rate.
bio-equip.cn
中文
